Clinical Trials Logo

Clinical Trial Summary

PD1, as an immune checkpoint inhibitor, has provided a new therapeutic approach for patients with cancer, including patients. Although immunotherapy has proven effective, most patients do not benefit from it because of a large proportion which developing primary and acquired resistance. However, there is still a lack of accurate and effective molecular biomarkers to accurately evaluate the drug resistance of patients treated with immune checkpoint inhibitors (ICI), so as to maximize the therapeutic effect in patients. Chromosomal instability (CIN) is one of the most prominent and common characteristics of solid tumors, accelerating the development of anti-cancer drug resistance, often leading to treatment failure and disease recurrence, which limits the effectiveness of most current treatments. Hence the aim of this study is to evaluate dynamic CIN continuously monitored in the blood of patients with lung cancer treated with ICIs with Ultrasensitive Chromosomal Aneuploidy Detection (UCAD) to establish a new molecular immune resistance evaluation index. Further, the correlation between the evolution of tumor cloning and ICI resistance in patients during treatment was analyzed based on the results of dynamic CIN detection. This not only evaluate the efficacy of the ICI treatment in real-time, but also enables better understanding and overcoming the resistance mechanism of immunotherapy in the future.


Clinical Trial Description

Immune checkpoint inhibitors (ICI) targeted to PD-1/PD-L1 axis has a higher response rate and lower incidence of side effects compared with anti-CTLA4, and has been proved to have survival advantages in many different malignant tumors, which has been approved as a second-line or first-line treatment for a growing number of malignancies, including lung cancer. As results of retrospective analysis led by Roberto Ferrara, although the efficacy of ICI treatment is obvious in non-small cell lung cancer (NSCLC), there are significant differences in efficacy and responsiveness in different patients. Therefore, establishing predictive biomarkers for immunotherapy is the key to maximizing the therapeutic effect and studying drug resistance. According to clinical trial data after immunotherapy, there are three main groups: (1) those who respond initially and continue to respond (responders); (2) those who have never responded (primary resistance); (3) Those who initially respond but eventually develop into disease progression (secondary resistance).Currently, PD-L1 expression is one of the most common biomarkers for immunotherapy, PD-L1 expression itself does not accurately predict immunotherapy response, due to that the many patients with higher PD-L1 have no response to clinical treatment, and many patients with lower PD-L1 respond better. Although tumor mutation burden (TMB ) used as a biomarker for the treatment of NSCLC by Opdivo could better differentiate the people who benefit compared with PD-L1, however, TMB as a biomarker to determine the criteria for the application of ICI treatment resistance is also limited because of its specific mechanism involved in tumor immune regulation needs to be further clarified and high cost of TMB detection using NGS for whole exome sequencing analysis.

As one of the most prominent and common features of solid tumors, chromosomal instability (CIN) accelerates the development of anticancer drug resistance, often leading to treatment failure and disease recurrence, which limits the effectiveness of most current treatments. Previous studies have shown that CIN promotes the emergence of multidrug resistance by providing higher levels of genetic diversity, leading to multidrug resistance. In NSCLC, the researchers found that genomic doubling and sustained dynamic CIN were associated with intratumoral heterogeneity and led to parallel evolution of CDNAs, including CDK4, FOXA1, and BCL11A. It is worth noting that the study found consistency in the variation of mutation levels, indicating that CIN in lung cancer is more likely to select driving events than other mutation processes. CIN enables cells to enter several different evolutionary trajectories and adapt to the selective pressure generated by treatment, which is the basis of drug resistance. Based on the above, CIN may become a more accurate and effective biomarker for the study of drug resistance mechanism of ICI in lung cancer. NGS technology can obtain more comprehensive genomic information while detecting cost reduction, making CIN detection more accurate and practical than FISH used for evaluating CIN in patient commonly.As a new Detection method based on NGS technology, Ultrasensitive Chromosomal Aneuploidy Detection (UCAD) has been developed in our previous study. In which, low-coverage whole-genome sequencing technology based on NGS was adopted to detect CIN of ctDNA in patients' peripheral blood, and bioinformatics analysis was performed to determine the risk of malignancy (or recurrence) and the extent of tumor burden and CIN. It has important clinical value in auxiliary diagnosis, therapeutic effect monitoring, recurrence and metastasis monitoring and prognosis evaluation of tumor patients.

This study proposes that continuous dynamic CIN is related to intratumor heterogeneity, which drives parallel evolution of somatic copy-number alterations (SCNAs) and promotes the emergence of drug-resistant clones by providing a higher level of genetic diversity of tumor cells, thus leading to drug resistance in patients treated with ICI. Investigators aimed to continuously monitor dynamic CIN in the blood of patients with lung cancer after second-line treatment with UCAD to establish a new molecular immune resistance evaluation index. Further, the correlation between the evolution of tumor cloning and ICI resistance in patients during treatment was analyzed based on the detection results of dynamic CIN. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04203095
Study type Observational
Source Shanghai Pulmonary Hospital, Shanghai, China
Contact Di Zheng, PhD
Phone 8613801683953
Email pulmonarysh_pg@126.com
Status Recruiting
Phase
Start date November 10, 2019
Completion date November 11, 2021

See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk